<DOC>
	<DOCNO>NCT03019237</DOCNO>
	<brief_summary>In study , participant receive either intranasal anti-IgE-antibodies ( n=5 ) intranasal allergen ( n=5 ) intranasal placebo ( n=5 ) . Blood sample obtain nasal administration study drug 3 , 5 8 week thereafter . In serum sample , specific total IgE level assess .</brief_summary>
	<brief_title>Effect Intranasal Anti-IgE Antibodies IgE Production</brief_title>
	<detailed_description>The intranasal challenge study perform 8 week outside birch pollen season ( November January ) randomize , double blind placebo-controlled study . During screen visit , 15 individual recruit accord eligibility criterion . They randomize 3 group ( i.n . administration anti-IgE antibody , Bet v 1 placebo ) . Intranasal administration take place three consecutive day serum sample take 3 , 5 , 8 week ( +/- 4 day ) treatment analysis total specific IgE level</detailed_description>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Anti-Idiotypic</mesh_term>
	<criteria>birch pollen allergy history anaphylaxis autoimmune diseases treatment corticosteroid , antihistamine , immunosuppressant drug , betablockers significant medical condition pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>